Salud financiera de hoja de balance de AlzeCure Pharma

Salud financiera controles de criterios 6/6

AlzeCure Pharma tiene un patrimonio de los accionistas total de SEK35.5M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK42.6M y SEK7.0M respectivamente.

Información clave

Ratio deuda-patrimonio

SEK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 39.19m
Patrimonio	SEK 35.52m
Total pasivo	SEK 7.04m
Activos totales	SEK 42.56m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK42.4M) de AC6 superan a sus pasivos a corto plazo (SEK7.0M).

Pasivo a largo plazo: AC6 no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: AC6 está libre de deudas.

Reducción de la deuda: AC6 no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AC6 tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: AC6 dispone de suficiente cash runway para 1 años si el flujo de caja libre sigue creciendo a tasas históricas de 2.6% cada año.

Salud financiera de hoja de balance de AlzeCure Pharma

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025

AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024

New minor risk - Shareholder dilution

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

New minor risk - Financial position

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New major risk - Revenue and earnings growth

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought €16k worth of stock

Chief Executive Officer recently bought €16k worth of stock

Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease

Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

New 90-day low: €0.74

New 90-day low: €0.77

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

AlzeCure Pharma AB (publ) Receives Approval to Start Clinical Phase I Trial with ACD856 in Alzheimer's Disease

Chief Executive Officer recently bought €92k worth of stock

Alzecure Gets Abstract on the Neurorestore Platform Against Alzheimer's Accepted for Poster Presentation At CTAD

AlzeCure Pharma AB Provides Scientific Update on Alzheimer's Disease and the Alzstatin Project Platform

New 90-day high - €1.07

AlzeCure Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 28, 2021

New 90-day high - €0.76

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera